February 19, 2025

Recurrent Hyperpigmented Patches After GLP-1 Therapy: What's Your Diagnosis?

A 62-year-old female developed fixed drug eruption following semaglutide administration, highlighting the importance of recognizing unusual dermatologic reactions during treatment with glucagon-like peptide-1 receptor agonists.

Conexiant

February 14, 2025

Study: Patients Trust Female Docs Less

Study findings and an interview with the lead investigator.

Conexiant

February 14, 2025

Laboratory Mentor Extraordinaire

Sitting Down With… Ann M Gronowski, Co-Division Chief of Laboratory and Genomic Medicine at Washington University School of Medicine

The Pathologist

February 12, 2025

FDA & EMA: Submitted Trial Data Discrepancies

Sample size discrepancies were identified in 13 trials (65%), with 8 differing by more than 10%.

Conexiant

February 10, 2025

Legally Speaking

Oliver Eikenberg describes his work as a consultant in regulatory affairs for in vitro diagnostic devices

The Pathologist

February 04, 2025

FDA Approves Clinical Trials for Genetically Modified Pig Kidney Transplants

FDA-cleared clinical trials will assess the safety, immunogenicity, and viability of genetically modified pig kidney transplants in patients with end-stage renal disease.

Conexiant

February 03, 2025

Igniting Innovation

How curiosity in pathology leads to better patient care

The Pathologist

January 28, 2025

FDA Approves Enhertu for Metastatic, HR-Positive, HER2-Low or -Ultralow Breast Cancer

Enhertu, a HER2-directed antibody-drug conjugate, was approved by the U.S. Food and Drug Administration for pretreated patients with metastatic HR-positive, HER2-low or HER2-ultralow breast cancer based on results from the DESTINY-Breast06 trial.

Conexiant

January 24, 2025

A1C Benefits Tied to H. pylori Treatment

Researchers evaluated the safety, efficacy, and glycemic benefits of vonoprazan-amoxicillin dual therapy for H. pylori eradication in type 2 diabetes patients.

Conexiant